SureTrader SPDR Advertisement
Home > Boards > US OTC > Biotechs >

Amarantus Bioscience Holdings Inc. (AMBS)

Add AMBS Price Alert      Hide Sticky   Hide Intro
Moderator: No Moderator joboggi, zoomboom, JJAAMMAANN, Rosym
Search This Board:
Last Post: 7/30/2015 12:32:54 PM - Followers: 724 - Board type: Free - Posts Today: 12


(AMBS) Amarantus BioScience Holdings, Inc. 

Amarantus is a biotechnology company developing treatments and diagnostics for diseases associated with neurodegeneration and protein misfolding-related apoptosis.
The company has licensed Eltoprazine, a Phase 2B ready Parkinsons Levadopa induced Dyskinesia.

The company has an exclusive worldwide license to the Lymphocyte Proliferation test ("LymPro Test®") is a
 diagnostic blood test for Alzheimer’s disease and is being evaluated as a diagnostic blood test for Traumatic Brain injury and Chronic Traumatic Encephalopathy.  (MANF) is a human growth factor that plays a key role in the prevention of apoptosis (cell death). It is being developed for the potential treatment of RP, Parkinson's disease, Wolfram syndrome, diabetes, Alzheimer's disease and traumatic brain injury.
Amarantus is a Founding Member of the Coalition for Concussion Treatment (#C4CT), a movement initiated in collaboration with Brewer Sports International seeking to raise awareness of new treatments in development for concussions and nervous-system disorders.
The Company also owns intellectual property rights for the diagnosis of Parkinson's Disease ("NuroPro") and the discovery of neurotrophic facotrs ("PhenoGuard").

ESS, previously known as PermaDerm®  is being developed to be the only tissue-engineered skin prepared from autologous (patient's own) skin cells consisting of both epidermal and dermal layers. A small harvested section of the patient's own skin can be grown to graft an area one hundred times its size in as little as thirty days. 

MSPrecise is a groundbreaking advancement for the diagnosis of multiple sclerosis and is anticipated to play a pivotal role given the current high rate of misdiagnosis
MSPrecise is a lab-developed test, and the successful completion of the validation study paves the way for this clinically important test to be commercialized in 2015. 
For further information, please visit, or connect with the company in FacebookTwitter, LinkedIn & Google+




Amarantus Diagnostics logo   Amarantus Announces Publication of a Clinical Study of MSPrecise(R) Diagnostic for Identification of Relapsing-Remitting Multiple Sclerosis (RRMS) in the Journal GENE
JULY 29, 2015
Amarantus BioScience Initiation of coverage Building up therapeutics assets
July 27, 2015
Amarantus Diagnostics Establishes Strategic Advisory Committee - Advisors Bring Over 30 Years of Expertise in Successfully Commercializing Molecular Diagnostics Companies
July 27, 2015 
SeeThruEquity Initiates Coverage on Amarantus BioScience Holdings, Inc. with a Price Target of $45.34
JULY 24, 2015
Amarantus Diagnostics Meets Primary and Secondary Endpoints in Blinded, Multi-Center LP-002 Clinical Study for LymPro(R) Blood Diagnostic for Alzheimer's Disease and Confirms LymPro's Fit-For-Purpose Use in Clinical Trials at the 2015 Alzheimer's Association International Conference(R)
July 22, 2015
Amarantus Announces First Patient Dosed in Eltoprazine Phase 2b Study for Treatment of Parkinson's Disease Levodopa-Induced Dyskinesia
JULY 20, 2015
Amarantus Closes Cutanogen Acquisition
By Jason Napodano, CFA  -  Wednesday, July 15, 2015

Amarantus Completes Acquisition of ESS From Lonza for the Treatment of Severe Burns  -  Amarantus Now Has Full Ownership of Cutanogen Corporation, Which Has Exclusive Worldwide License to Orphan Drug Product Candidate Engineered Skin Substitute (ESS)  -  July 15, 2015
Amarantus to Commence Trading on the OTCQX Marketplace Under Existing Ticker Symbol AMBS - Company Progressing Toward a National Stock Exchange Listing. -  July 13, 2015
Amarantus Announces Issuance of United States Patent No. 9,066,903 Covering Proprietary Methods of Administration of Eltoprazine for the Treatment of Parkinson's Disease  -  Patent Provides IP Protection for Lead Product Candidate Eltoprazine for the Treatment of Parkinson's Disease    -   June 30, 2015
Amarantus Sets Sights On NASDAQ
Jason Napodano, CFA   -   May 29, 2015  

Amarantus Enters Into CRO Agreement With Chiltern International to Commence Phase 2b Clinical Development of Eltoprazine in Parkinson's Disease Levodopa-Induced Dyskinesia - Company Completes Investigator Meetings in U.S. and E.U. in Preparation for Study Launch -  Enrollment and Dosing for 60-Patient PD-LID Study on Track to Commence 2Q 2015 
May 21, 2015
Amarantus Reports First Quarter 2015 Financial Results and Business Overview  - Eltoprazine Phase 2b clinical program on track to commence in 2Q 2015 -     
May 20, 2015   
Amarantus Announces Successful Delivery and Distribution of MANF in Preclinical Model to Brain Areas Involved in Parkinson's Disease - Demonstrated MANF Can be Precisely Delivered to Parkinson's-Associated Brain Areas.
May 15, 2015
MANF Begins its March Towards the Clinic
May 14th, 2015

Amarantus Enters Into cGMP Manufacturing Agreement With Catalent Biologics for Production of MANF for Human Clinical Studies
May 14, 2015
Amarantus Receives Notice of Allowance for U.S. Patent Application Covering Proprietary Methods of Administration and Compositions in the Treatment of Parkinson's Disease  -  Patent Issuance Will Provide IP Protection for Lead Product Candidate Eltoprazine for Treatment of Parkinson's Disease Levodopa-Induced Dyskinesia (PD-LID)
May 13, 2015
Amarantus Announces the Presentation of Data Showing MANF's Positive Effect on Retinal Function at Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting
May 7, 2015 
Amarantus Receives Notice of Allowance for U.S. Patent Application Covering Proprietary Compositions of Matter and Methods of Use for MANF
May 5, 2015
Amarantus Granted European Union Orphan Drug Designation for MANF for the Treatment of Retinitis Pigmentosa
April 29, 2015

More News



 Gerald E. Commissiong on LymPro 
Published on Jul 24, 2015

Predicting Alzheimer's before it starts
 Published on Apr. 8, 2015

Developing an Accurate Test for Multiple Sclerosis
Mar. 5, 2014

SNNLive - Amarantus BioScience Holdings, Inc
Dec. 12, 2014


Amarantus BioScience
Oct. 19, 2014




Company Information

Amarantus BioScience Holdings, Inc.
655 Montgomery Street
Suite 900
San Francisco, CA 94111


c/o ICS Corporate Services SA
29 quai du Mont Blanc
CH-1201 Geneva

Phone: (415) 688-4484
Fax: (408) 852-4427

Gerald's email address

IR Calendar 



Jenene Thomas Communications
Jenene Thomas
T: 908-938-1475



VStock Transfer, LLC
Allison Niccols
77 Spruce Street
Suite 201
Cedarhurst, N 11516
T: 212-828-8436
F: 646-536-3179


Throughout my 50+ years in the biopharmaceutical industry, I have seen many programs with great promise, but very few programs that possess the fundamentally groundbreaking scientific potential to modify disease biology inherent in MANF This vast potential for MANF is what makes today’s announcement personally so exciting for me, as the initiation of IND-enabling studies (which start with initiation of clinical grade manufacturing) has been the rate-limiting step for true product development value creation for MANF not only for the ophthalmology programs, but also the rest of the MANF pipeline.

  Dr. Wen commented, "We continue to see very encouraging preclinical data with MANF. I am looking forward to continue further development of MANF in collaboration with Amarantus, as I believe it has the potential to address RP, as well as other ophthalmologic disorders with serious unmet need and improve the quality of life of patients where no viable treatments exist today."
More information
         “We are very pleased with the data generated in RP from Dr. Wen’s lab at University of Miami’s Bascom Palmer Eye Institute, one of the world’s most prestigious ophthalmology research and treatment centers,” said Gerald E. Commissiong, President & CEO of Amarantus BioScience Holdings, Inc. “Given the recent granting of orphan drug designations in both the US and EU, the presentation of this data is very timely as we build momentum for MANF in this devastating orphan indication, as well as continue to further establish the MANF orphan ophthalmology franchise.

   Amarantus Receives Orphan Drug Designation for MANF From U.S. Food and Drug Administration for Treatment of Retinitis Pigmentosa
 "We are very pleased to receive orphan drug designation for MANF in RP. This represents an important milestone for the company as well as a significant step forward for our clinical and regulatory strategy," said Gerald E. Commissiong
 Most people with RP are legally blind by age 40. It is estimated that the market opportunity for Retinitis Pigmentosa exceeds $10B annually.

        smiley    BUSINESS UPDATE CONFERENCE CALL - Presentation (PDF)  May 27, 2015   yes
       Amarantus BioScience's (AMBS) CEO Gerald Commissiong Hosts Business Update Conference Call (Transcript)

                           2 Conferences

Annual Meeting at NASDAQ MarketSite, - Monday, August 3, 2015  10:30 a.m Eastern Time  - The Opening and Closing Bell ceremonies at the NASDAQ MarketSite in 4 Times Square, New York, NY 1003 serve as a platform to generate exposure for your company, make a news announcement or celebrate corporate milestones.

First MANF & CDNF Proteins Symposium - Two-Day International Symposium, San Francisco, CA  -  September 14 -15, 2015 

  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
Current Price
Bid Ask Day's Range
AMBS News: Amarantus Announces Publication of a Clinical Study of MSPrecise(R) Diagnostic for Identification of Relapsing-Remitting Mult... 07/29/2015 07:35:00 AM
AMBS News: Amarantus Diagnostics Establishes Strategic Advisory Committee 07/27/2015 07:35:00 AM
AMBS News: Current Report Filing (8-k) 07/22/2015 04:16:56 PM
AMBS News: Amarantus Diagnostics Meets Primary and Secondary Endpoints in Blinded, Multi-Center LP-002 Clinical Study for LymPro(R) Bloo... 07/22/2015 10:30:00 AM
#115945  Sticky Note NASDAQ MarketSite on Aug. 3, 2015 Rosym 07/11/15 11:47:57 AM
#104968  Sticky Note MJFF is firm with their notion that NFs joboggi 07/17/14 02:01:07 AM
#116538   Yes, Lympro the gold standard. leslunier 07/30/15 12:32:54 PM
#116537   I guess many, myself included view(ed) them as Ragnaroc 07/30/15 12:24:15 PM
#116536   Everyone is upset because.. JJAAMMAANN 07/30/15 11:55:20 AM
#116535   Their commitment to Lympro after all these efforts Ragnaroc 07/30/15 10:03:16 AM
#116534   TOXIC Financier DOMINION adds nearly 5% to ownership. Sgt. Pepper 07/30/15 09:37:06 AM
#116533   Warning! 150-1 Reverse Split in play. Shares will Sgt. Pepper 07/30/15 09:36:33 AM
#116532   Beware! PRE RS was trading at .04 Sgt. Pepper 07/30/15 09:36:18 AM
#116531   ah, the pps is not going to joboggi 07/30/15 08:05:48 AM
#116530   I would tend to agree with this type Salexander1 07/30/15 07:07:04 AM
#116529   Weekly TA Chart JPetroInc 07/30/15 06:06:51 AM
#116528   The 70/70 is the standard right now and GS1 07/30/15 01:35:40 AM
#116527   When the number of buys is eclipsed by joboggi 07/30/15 01:00:11 AM
#116526   Pps sucks but volume is awesome. Lots of TekNerd 07/29/15 11:24:02 PM
#116525   Right! TekNerd 07/29/15 07:52:55 PM
#116524   I don't understand why everyone is so upset. youngncurious 07/29/15 07:51:25 PM
#116523   0.0244 cents a share. joboggi 07/29/15 05:54:47 PM
#116522   Just remember, you can't bring your skateboards inside, jeffshir 07/29/15 05:40:52 PM
#116521   Things are going to get heated Mon. at JPetroInc 07/29/15 05:27:18 PM
#116520   It's been in the works for a long SidVicious 07/29/15 12:38:54 PM
#116519 el_lobodewallst 07/29/15 12:33:32 PM
#116518   Got it to work, it was my ISP Ragnaroc 07/29/15 12:14:22 PM
#116517   Do you still believe in Ambs and mgmt Ruffieruff 07/29/15 11:47:47 AM
#116516   Sure seems that way. Shareholders need to step Ruffieruff 07/29/15 11:44:40 AM
#116515   Say goodbye to all your $$$$ 27times 07/29/15 11:01:52 AM
#116514   i would not say it if GC would Alapis 07/29/15 10:59:39 AM
#116513   These type of threats don't belong on here brharris 07/29/15 10:58:02 AM
#116512   no balls and no brain...but fraudulent genes -....inherited Alapis 07/29/15 10:48:31 AM
#116511   good point Alapis 07/29/15 10:42:51 AM
#116510   which he doesn´t have! Jotte 07/29/15 10:42:07 AM
#116508   now it Looks like ist going down, down, down.... Jotte 07/29/15 10:38:09 AM
#116507   seems like the cheerleaders have no more Alapis 07/29/15 10:34:29 AM
#116506   GC does everything to avoid critical questions...he has Alapis 07/29/15 10:17:49 AM
#116505   I cannot attend and also the proxy number Ragnaroc 07/29/15 10:11:31 AM
#116504   question for the cheerleaders: why did GC never Alapis 07/29/15 10:10:56 AM
#116503   Gerald Commissiong ?@G_Commish 2h2 hours ago der_deutschetrader 07/29/15 09:36:03 AM
#116502   TOXIC Financier DOMINION adds nearly 5% to ownership. Sgt. Pepper 07/29/15 09:34:06 AM
#116501   Warning! 150-1 Reverse Split in play. Shares Sgt. Pepper 07/29/15 09:33:52 AM
#116500   shareholders should send him to hell at the meeting Alapis 07/29/15 09:33:44 AM
#116499   Beware! PRE RS was trading at .04 Sgt. Pepper 07/29/15 09:33:38 AM
#116498   old news Alapis 07/29/15 09:23:35 AM
#116497   Amarantus Announces Publication of a Clinical Study of IPO$ 07/29/15 09:22:09 AM
#116496   what can you expect from a silly liar Alapis 07/29/15 09:12:43 AM
#116495   It's these type of statements GC should avoid!! brharris 07/29/15 09:10:35 AM
#116494   so am i...i truly hope the SEC or Alapis 07/29/15 09:06:30 AM
#116493   His lies have controlled the stock price. Him Loco Motion 07/29/15 09:04:06 AM
#116492   With one patient enrolled. WOW!!! leslunier 07/29/15 08:58:31 AM
#116491   this shameless liar only wants a yes for Alapis 07/29/15 08:53:30 AM
#116490   Gerald Commissiong ?@G_Commish 2h2 hours ago Rosym 07/29/15 08:50:33 AM
#116489   Great! Means more red today. SidVicious 07/29/15 08:35:21 AM
#116487   Amarantus Announces Publication of a Clinical Study of JPetroInc 07/29/15 08:15:44 AM